Collectively, TIAM1 variants associated with better outcome in neuroblastoma patients and therefore, suggest that inhibiting TIAM1 in neuroblastoma could be used in conjunction with conventional therapy to improve outcome. This evidence concerns the gene TIAM1 and neuroblastoma.